Pharmacist intervention for glycaemic control in the community (the RxING study)

BMJ Open

Volumn 3, Issue 9, 2013, Pages

  Al Hamarneh, Yazid N ^a   Charrois, Theresa ^b   Lewanczuk, Richard ^a   Tsuyuki, Ross T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CURTIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN GLARGINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE DURATION; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PHARMACIST; POINT OF CARE TESTING; QUALITY OF LIFE; TREATMENT RESPONSE;

EID: 84885336488     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003154     Document Type: Article

References (19)

1. World Health Organization. Diabetes. 2012. http://www.who.int/ mediacentre/factsheets/fs312/en/ (accessed Feb 2013).
2. Lipscombe LL, Hux JE Trends in diabetes prevalence, incidence and mortality in Ontario, Canada 1995-2005: a population based study. Lancet 2007;369:750-6. (Pubitemid 46321630)
3. World Health Organization. Diabetes: the cost of diabetes. 2012. http://www.who.int/mediacentre/factsheets/fs236/en/ (accessed Feb 2013).
4. Al Hamarneh Y.N., Rosenthal M, Tsuyuki RT Glycemic control in community-dwelling patients with type 2 diabetes. Can Pharm J 2012;2:68-9e1.
5. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999;7:139-53.
6. Polonsky WH, Jackson RA What's so tough about taking insulin? Clin Diabetes 2004;22:147-50.
7. Gerstein HC, Yale JF, Harris S.B., et al A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT study. Diabet Med 2006;23:736-42. (Pubitemid 44366071)
8. Canadian Diabetes Association. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008;32:s1-201.
9. Harris S, Yale JF, Dempsey E, et al Can family physicians help patients initiate basal insulin therapy successfully? Randomized trial of patient-titrated insulin glargine compared with standard oral therapy: Lessons for family practice from Canadian INSIGHT trial. Can Fam Physician 2008;54:550-8. (Pubitemid 351554055)
10. Polonsky WH, Fisher L, Guzman S., et al Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care 2005;28:2543-5. (Pubitemid 41384310)
11. Shiu JR, Simpson SH, Johnson J.A., et al Quantifying opportunities to affect diabetes management in the community. Can Pharm J 2006;139:37-8. (Pubitemid 44049339)
12. O'Donovan D., Byrne S, Sahm L. The role of pharmacists in control and management of type 2 diabetes mellitus; a review of the literature. J Diabetol 2011;1:5-21.
13. Wubben DP, Vivian EM Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy 2008;28:421-36. (Pubitemid 351466454)
14. Armour CL, Taylor SJ, Houriham F, et al Implementation and evaluation of Australian pharmacists' diabetes care services. J Am Pharm Assoc 2004;44:455-66.
15. Fornos JA, Andres NF, Andres J.C., et al A pharmacotherapy follow-up program in patients with type-2 diabetes in community pharmacies in Spain. Pharm World Sci 2006;28:65-72. (Pubitemid 44510949)
16. Krass I, Armour CL, Mitchell B, et al The pharmacy diabetes care program: assessment of a community pharmacy diabetes service model in Australia. Diabet Med 2007;24:677-83. (Pubitemid 46808869)
17. Strange P. Treat-to-target insulin titration algorithms when initiating long or intermediate acting insulin in type 2 diabetes. J Diabetes Sci Technol 2007;1:540-8.
18. Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life and adherence. Clin Med Res 2008;6:54-67.
19. Rosenstock J, Dailey G, Massi-Benedetti M, et al Reduced hypoglycemia risk with insulin glargine in type 2 diabetes. Diabetes Care 2005;28:950-5.